Virus

Manuel Ascano team validates an inhibitor of the cGAS-STING signaling pathway, which is important for cellular innate immunity against bacteria, viruses, and our own damaged DNA. Read More

Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months. Read More

Genomic sequences have revealed that Florida is a major source of a mosquito-borne virus that causes disease in horses and humans. Read More

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members. Read More

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses. Read More

Compounds developed at Vanderbilt University may offer a new way to block influenza infection. Read More

Understanding how the immune system responds to the respiratory virus HMPV is crucial for developing vaccines and anti-viral treatments. Read More

Virus-like particles containing a protein from human metapneumovirus are a promising vaccine candidate for this respiratory virus. Read More

Understanding how chikungunya virus binds to and enters cells offers a new target for antiviral medications. Read More

Vanderbilt’s James Crowe Jr., M.D., and a collaborator in Texas have been awarded a $4.4 million grant from the U.S. Department of Defense to study new ways to treat and prevent Ebola and Marburg viruses. Read More